Many Americans unaware of increased risk to UV exposure for certain drugs, light-colored eyes

Article

The American Academy of Ophthalmology recently released results of a poll that found the majority of Americans are unaware of the increased risks to ultraviolet (UV) light exposure that are linked to common drugs and having light-colored eyes.

San Francisco-The American Academy of Ophthalmologyrecently released results of a poll that found the majority of Americans are unaware of the increased risks to ultraviolet (UV) light exposure that are linked to common drugs and having light-colored eyes. 

UV exposure can lead to an increased risk of eye cancer, cataracts, photokeratitis, and pterygium. Despite the danger, the poll found nearly half of Americans are unaware that medications can cause photosensitivity-even though about one-third of adults take drugs that increase their susceptibility to UV damage. And while 54 percent of Americans have blue, green, or hazel eyes, only 32 percent of those with light eyes know that they are more susceptible to UV damage.

To make matters worse, the poll found that while 83 percent of Americans wear sunglasses, only about half of those who do wear sunglasses check for a UV protection label before purchasing a pair. And just 32 percent said they make their children wear UV-blocking sunglasses. 

Next: Louisiana to allow ODs to perform certain surgeries

Popular diabetes drug linked to reduced glaucoma risk

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
At ARVO 2025, Mark Bullimore, MCOptom, PhD, emphasized the need for more accurate, condition-specific tools in evaluating myopic eye growth and treatment efficacy.
Dr Luke Lindsell discusses retinal therapy and geographic atrophy at Controversies in Modern Eye Care 2025
Neda Shamie, MD, speaks on cataract and refractive surgery at CIME 2025.
Dr Selina McGee shares thoughts on pharmacological presbyopia correction at Controversies in Modern Eye Care 2025
Paul Hammond, OD, FAAO, presents a poster at ARVO 2025 on the creation of a conversion factor between 2 OCT devices to monitor glaucoma progression
What to know about legislative moves that have been made through May this year.
CIME 25: Dilsher Dhoot, MD, FASRS, is excited about emerging retinal therapies.
Robert Maloney, MD, MA, at the 2025 Controversies in Modern Eye Care meeting
Dr Jacob Lang at the 2025 Controversies in Modern Eye Care meeting
© 2025 MJH Life Sciences

All rights reserved.